[
  {
    "ts": null,
    "headline": "Here’s What Analysts Think About Halozyme Therapeutics (HALO)",
    "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or […]",
    "url": "https://finnhub.io/api/news?id=67c00afcd5e1859a46eff15d083a3dbf92ff70900841a3ee0e2028f4fb1f3b90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767199309,
      "headline": "Here’s What Analysts Think About Halozyme Therapeutics (HALO)",
      "id": 137950171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or […]",
      "url": "https://finnhub.io/api/news?id=67c00afcd5e1859a46eff15d083a3dbf92ff70900841a3ee0e2028f4fb1f3b90"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares. Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was […]",
    "url": "https://finnhub.io/api/news?id=1a0fa66636fbd5ed091ca0064809eb15a8210d219f65f4c6d1b2ead6db9d097f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767197565,
      "headline": "AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share",
      "id": 137950172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares. Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was […]",
      "url": "https://finnhub.io/api/news?id=1a0fa66636fbd5ed091ca0064809eb15a8210d219f65f4c6d1b2ead6db9d097f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
    "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
    "url": "https://finnhub.io/api/news?id=99a41ad6d5957640fad350a769e0fb968bc194a5106242f6b7878d63c84d7775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767191682,
      "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
      "id": 137950161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
      "url": "https://finnhub.io/api/news?id=99a41ad6d5957640fad350a769e0fb968bc194a5106242f6b7878d63c84d7775"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?",
    "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=07997d0de1a1c2070d5fc518aae8b670f5ed1bee7264b26252b4ed9580c55ea3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767191402,
      "headline": "Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?",
      "id": 137950174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=07997d0de1a1c2070d5fc518aae8b670f5ed1bee7264b26252b4ed9580c55ea3"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock",
    "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=08dff206bda8c49e979a50f42cac8a9aa2e2593facac187fdf94c8c93a8602bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767189607,
      "headline": "Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock",
      "id": 137950175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=08dff206bda8c49e979a50f42cac8a9aa2e2593facac187fdf94c8c93a8602bc"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Industrials 2025: These Three Unexpected Stocks Top Nvidia",
    "summary": "The Dow Jones' top five stocks of the year included two names investors may not have expected to find next to AI giants like Nvidia and IBM.",
    "url": "https://finnhub.io/api/news?id=1f84b8b636fff86ab46b55b9ad0dc04cef4a640aeaeee405e53558be3387bd90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767188353,
      "headline": "Dow Jones Industrials 2025: These Three Unexpected Stocks Top Nvidia",
      "id": 137950176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Dow Jones' top five stocks of the year included two names investors may not have expected to find next to AI giants like Nvidia and IBM.",
      "url": "https://finnhub.io/api/news?id=1f84b8b636fff86ab46b55b9ad0dc04cef4a640aeaeee405e53558be3387bd90"
    }
  },
  {
    "ts": null,
    "headline": "BAYRY's 2025 Revival: Will the Momentum Continue in 2026?",
    "summary": "BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.",
    "url": "https://finnhub.io/api/news?id=33503a5941c547b4923923d59680328844b4df3dd69ca762e292353d57a08eb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767186600,
      "headline": "BAYRY's 2025 Revival: Will the Momentum Continue in 2026?",
      "id": 137950177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.",
      "url": "https://finnhub.io/api/news?id=33503a5941c547b4923923d59680328844b4df3dd69ca762e292353d57a08eb9"
    }
  },
  {
    "ts": null,
    "headline": "How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?",
    "summary": "BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.",
    "url": "https://finnhub.io/api/news?id=f03f64d6bf473144f8194e24d3e645b083a2da582c0bb1af1885b42b359499f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767183660,
      "headline": "How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?",
      "id": 137950178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.",
      "url": "https://finnhub.io/api/news?id=f03f64d6bf473144f8194e24d3e645b083a2da582c0bb1af1885b42b359499f8"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For January 2026",
    "summary": "Best Dividend Aristocrats For January 2026",
    "url": "https://finnhub.io/api/news?id=0efd569dae7709ab1787c907709a5e73b4919b4c811f73b8cd583628148221e4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767170878,
      "headline": "Best Dividend Aristocrats For January 2026",
      "id": 137948634,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0efd569dae7709ab1787c907709a5e73b4919b4c811f73b8cd583628148221e4"
    }
  }
]